USA Today

Novo GLP-1 drug shows less lean mass loss than rivals, study says

Eli Lilly's LLY.N GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's NOVOb.CO semaglutide, but at a greater expense to muscles and connective tissues, according to a ...
Healio

‘Muscle matters’: The challenge of preserving lean mass during obesity treatment

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Some patient populations may be at higher risk for lean ...
Hosted on MSN

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds

April 16 (Reuters) - Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater expense to muscles and connective tissues, according to ...
Reuters

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds

GLP-1 drugs yielding greater weight loss have worse effects on lean body mass Patients on tirzepatide lost more muscle and other non-fat tissues than patients on semaglutide Exercise during treatment ...